




Applying the platform process and suite of ready-to-go analytical assays from candidate selection accelerates pathway to DP available for first clinical study. Using same process and suite of ready-to-go assays builds data from Day 1 for IND/IMPD and continues to build for BLA/MAA, avoiding costly comparability and bridging studies